AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26732104 — intervention group
Group type: EXPERIMENTAL
Intervention: Transumbilical two-port laparoscopic varicocele ligation (TTLVL)
Number of subjects: 90
Study 26732104 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic varicocele ligation (CLVL)
Number of subjects: 90
Study 26009929 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg bid)
Number of subjects: 40
Study 26009929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23439357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 120
Study 23439357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 120
Study 23439357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ulinastatin and tranexamic acid
Number of subjects: 120
Study 23439357 — intervention group
Group type: COMPARATOR
Intervention: Control (Physiological saline)
Number of subjects: 120
Study 21572483 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with Venturi‐like flow generator
Number of subjects: 20
Study 21572483 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with Boussignac's device
Number of subjects: 20
Study 19154840 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing vertical center of mass (COM) displacement during gait
Number of subjects: 10
Study 19154840 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing vertical center of mass (COM) displacement during gait
Number of subjects: 10
Study 17006811 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-associated MRSA (CA-MRSA) strains
Number of subjects: 37
Study 17006811 — intervention group
Group type: COMPARATOR
Intervention: Healthcare-associated MRSA (HA-MRSA) strains
Number of subjects: 37
Study 17006811 — intervention group
Group type: COMPARATOR
Intervention: Healthcare-associated infections
Number of subjects: 37
Study 17006811 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-MRSA infections
Number of subjects: 37
Study 17006811 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CA-MRSA and HA-MRSA infections
Number of subjects: 37
Study 12601217 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mol/L gadobutrol
Number of subjects: 43
Study 12601217 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mol/L gadobutrol
Number of subjects: 43
Study 10672435 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of controlled‐release melatonin
Number of subjects: 8
Study 10672435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9574377 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforating appendicitis
Number of subjects: 519
Study 9574377 — intervention group
Group type: COMPARATOR
Intervention: Nonperforating appendicitis
Number of subjects: 519
Study 7952047 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alpha-glycerophosphorylcholine (1 g)
Number of subjects: 8
Study 7952047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2959917 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretin 40 mg
Number of subjects: 9
Study 2959917 — intervention group
Group type: COMPARATOR
Intervention: Etretinate 40 mg
Number of subjects: 9
Study 31695168 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, Sertraline, Venlafaxine-XR (antidepressants)
Number of subjects: 163
Study 30091952 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab in combination with methotrexate
Number of subjects: 0
Study 30091952 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with methotrexate
Number of subjects: 0
Study 28647668 — intervention group
Group type: EXPERIMENTAL
Intervention: Early improvement (Hamilton Depression Rating Scale reduction > 20% after 14 days of treatment)
Number of subjects: 889
Study 28647668 — intervention group
Group type: EXPERIMENTAL
Intervention: Early improvement with melancholic features
Number of subjects: 889
Study 28647668 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined marker of early non-improvement and melancholic features
Number of subjects: 889
Study 25808818 — intervention group
Group type: COMPARATOR
Intervention: Favipiravir (acute administration for 1 day)
Number of subjects: 0
Study 25808818 — intervention group
Group type: COMPARATOR
Intervention: Favipiravir (extended administration for 6 days)
Number of subjects: 0
Study 25808818 — intervention group
Group type: COMPARATOR
Intervention: Favipiravir co-administration
Number of subjects: 0
Study 23845297 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivatives (EMD)
Number of subjects: 20
Study 23845297 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Oss Collagen
Number of subjects: 20
Study 20501622 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin 3 mg
Number of subjects: 32
Study 18707820 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin (area under the curve of 2) during RT
Number of subjects: 18
Study 18707820 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and etoposide every 3 weeks during RT (Trans‐Tasman Radiation Oncology Group 96:07 study)
Number of subjects: 18
Study 16517502 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of DHA and 150 mg of EPA
Number of subjects: 46
Study 16517502 — intervention group
Group type: COMPARATOR
Intervention: Control group (without DHA and EPA)
Number of subjects: 46
Study 12640214 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg)
Number of subjects: 246
Study 12640214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 10813579 — intervention group
Group type: EXPERIMENTAL
Intervention: Small for gestational age (SGA)
Number of subjects: 36
Study 10813579 — intervention group
Group type: COMPARATOR
Intervention: Appropriate for gestational age (AGA)
Number of subjects: 36
Study 8800165 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation group (n = 60; 15 micrograms.kg‐1 fentanyl and 2 to 6 mg.kg‐1.hour‐1 propofol and isoflurane)
Number of subjects: 120
Study 8800165 — intervention group
Group type: COMPARATOR
Intervention: Conventional extubation group (n = 60; 50 micrograms.kg‐1 fentanyl and 0.1 mg.kg‐1 midazolam and isoflurane)
Number of subjects: 120
Study 1386224 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 64
Study 1386224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 50 micrograms
Number of subjects: 64
Study 1386224 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 mg with Sufentanil 25 micrograms
Number of subjects: 64
Study 1386224 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 64
Study 6365351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n = 19)
Number of subjects: 28
Study 6365351 — intervention group
Group type: COMPARATOR
Intervention: Muscle relaxation and low-level exercise (n = 9)
Number of subjects: 28
Study 6365351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 31409559 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame training
Number of subjects: 115
Study 31409559 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 115
Study 31409559 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 115
Study 29497063 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 118
Study 29497063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 29497063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Simvastatin and Placebo)
Number of subjects: 118
Study 27411172 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) and arachidonic acid (AA) levels in the umbilical cord
Number of subjects: 229
Study 27411172 — intervention group
Group type: EXPERIMENTAL
Intervention: AA:DHA ratio in the umbilical vein
Number of subjects: 229
Study 27411172 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal LCPUFA status
Number of subjects: 229
Study 23632408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton swabs soaked in 4% lidocaine applied to the globe with moderate pressure
Number of subjects: 48
Study 23632408 — intervention group
Group type: COMPARATOR
Intervention: 3.5% lidocaine gel applied without pressure
Number of subjects: 48
Study 22094937 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (75 mg/m²) + Paclitaxel (175 mg/m²)
Number of subjects: 287
Study 22094937 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m²) + Paclitaxel (155 mg/m²) + Capecitabine (825 mg/m² BID for 14 days)
Number of subjects: 287
Study 22094937 — intervention group
Group type: COMPARATOR
Intervention: Control group (ET)
Number of subjects: 287
Study 19016569 — intervention group
Group type: COMPARATOR
Intervention: 20-mL syringe with vacuum obtained by a hand-grip device (Group 1)
Number of subjects: 200
Study 19016569 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mL Vacutainer connected to the needle (Group 2)
Number of subjects: 200
Study 17451416 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing
Number of subjects: 34
Study 17451416 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing + Flossing
Number of subjects: 34
Study 17451416 — intervention group
Group type: COMPARATOR
Intervention: Direct measure of IPP (plaque weight)
Number of subjects: 34
Study 15281697 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week psychoeducational group intervention
Number of subjects: 27
Study 12452872 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA irradiation (cumulative doses of 96 J cm‐2 for skin type II and 126 J cm‐2 for skin type III)
Number of subjects: 44
Study 12452872 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed (control group)
Number of subjects: 44
Study 9520071 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated IgM anti‐GM1 levels in patients with neuropathies (NP)
Number of subjects: 243
Study 9520071 — intervention group
Group type: COMPARATOR
Intervention: Median levels of IgM‐, IgG‐, (IgM+IgG)‐, and C5b‐9‐binding anti‐GM1
Number of subjects: 243
Study 9520071 — intervention group
Group type: EXPERIMENTAL
Intervention: Median levels of IgG‐ and (IgM+IgG)‐anti‐GM1
Number of subjects: 243
Study 9520071 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement‐binding activity
Number of subjects: 243
Study 9520071 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐GM1 level (IgM+IgG)
Number of subjects: 243
Study 8129608 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative, noninvasive: The redox tolerance test (RTT) measuring changes in arterial ketone body ratio in response to 75 g of oral glucose loading.
Number of subjects: 40
Study 8129608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative, invasive: Cytochrome c oxidase activity and energy charge of the liver.
Number of subjects: 40
Study 8129608 — intervention group
Group type: COMPARATOR
Intervention: Group B (RTI < 0.5)
Number of subjects: 40
Study 2679237 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25 micrograms fentanyl
Number of subjects: 56
Study 2679237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 56
Study 31645305 — intervention group
Group type: EXPERIMENTAL
Intervention: Low titer group O whole blood
Number of subjects: 0
Study 31645305 — intervention group
Group type: COMPARATOR
Intervention: Blood components therapy
Number of subjects: 0
Study 29019364 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry treatment (BB; 300 g of blueberry)
Number of subjects: 24
Study 29019364 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (C; 300 mL of water with sugar)
Number of subjects: 24
Study 29019364 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry treatment with smoking (BS; 300 g of blueberry + smoking)
Number of subjects: 24
Study 29019364 — intervention group
Group type: COMPARATOR
Intervention: Control treatment with smoking (CS; 300 mL of water with sugar + smoking)
Number of subjects: 24
Study 29019364 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking treatment (S)
Number of subjects: 24
Study 23897051 — intervention group
Group type: EXPERIMENTAL
Intervention: Transposterior arch lateral mass screw fixation
Number of subjects: 66
Study 23897051 — intervention group
Group type: COMPARATOR
Intervention: Lateral mass screw fixation
Number of subjects: 66
Study 23456557 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (self-report and objective measures)
Number of subjects: 1527
Study 23456557 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (accelerometer data subsample)
Number of subjects: 1527
Study 21332563 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery (group 1)
Number of subjects: 40
Study 21332563 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery (group 2)
Number of subjects: 40
Study 21332563 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nitroglycerine use
Number of subjects: 40
Study 19826306 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially formulated water
Number of subjects: 21
Study 19826306 — intervention group
Group type: COMPARATOR
Intervention: Bottled water (placebo)
Number of subjects: 21
Study 19826306 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte beverage (6% or 60 g L(‐1))
Number of subjects: 21
Study 17082474 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF) 10 microg/kg for 5 days
Number of subjects: 36
Study 17082474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15554360 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G/4G genotype
Number of subjects: 547
Study 15554360 — intervention group
Group type: COMPARATOR
Intervention: 4G/5G genotype
Number of subjects: 547
Study 15554360 — intervention group
Group type: COMPARATOR
Intervention: 5G/5G genotype
Number of subjects: 547
Study 15554360 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1 plasma levels
Number of subjects: 547
Study 11297210 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (10(6) KIU after induction of anesthesia and 10(6) KIU in pump prime)
Number of subjects: 36
Study 11297210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 36
Study 9226484 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of water soluble fibre (guar gum) daily for 14 months
Number of subjects: 31
Study 9226484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre consuming group with 50-80% compliance (group B)
Number of subjects: 31
Study 9226484 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 9226484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplementation
Number of subjects: 31
Study 8213300 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive program
Number of subjects: 1100
Study 8213300 — intervention group
Group type: COMPARATOR
Intervention: No Incentive
Number of subjects: 1100
Study 2888185 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg HOE 760
Number of subjects: 10
Study 2888185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28084834 — intervention group
Group type: COMPARATOR
Intervention: Progressive Neck Exercise Program
Number of subjects: 0
Study 28084834 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Behavioral Modification Therapy
Number of subjects: 0
Study 27480314 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation with daily sedation interruption
Number of subjects: 423
Study 27480314 — intervention group
Group type: COMPARATOR
Intervention: Protocolized sedation alone
Number of subjects: 423
Study 27480314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime sedation
Number of subjects: 423
Study 27480314 — intervention group
Group type: COMPARATOR
Intervention: Daytime sedation
Number of subjects: 423
Study 25527842 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid and local anaesthetic injections administered by a physiotherapist
Number of subjects: 64
Study 25527842 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid and local anaesthetic injections administered by an orthopaedic surgeon
Number of subjects: 64
Study 22898679 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib with chemotherapy (good-risk group)
Number of subjects: 178
Study 22898679 — intervention group
Group type: COMPARATOR
Intervention: No imatinib with chemotherapy (good-risk group)
Number of subjects: 178
Study 22898679 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib with chemotherapy (as-treated analysis, good-risk group)
Number of subjects: 178
Study 22898679 — intervention group
Group type: COMPARATOR
Intervention: No imatinib with chemotherapy (as-treated analysis, good-risk group)
Number of subjects: 178
Study 22898679 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib with chemotherapy (poor-risk group)
Number of subjects: 178
Study 20384990 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to clinical practice guidelines (CPGs)
Number of subjects: 0
Study 20384990 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment or treatment not according to CPGs
Number of subjects: 0
Study 20384990 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of sarcoma
Number of subjects: 0
Study 20384990 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rate
Number of subjects: 0
Study 18362489 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 4 weeks
Number of subjects: 30
Study 18362489 — intervention group
Group type: COMPARATOR
Intervention: Control (no finasteride)
Number of subjects: 30
Study 16120545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor vascularity assessed by Chalkley counting (TVC) in prostate core biopsies
Number of subjects: 50
Study 16120545 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without PSA recurrence)
Number of subjects: 50
Study 12163992 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiation with cisplatin 40 mg/m2 weekly for 6 courses and HDR brachytherapy (7 Gy in point A per fraction, total dose 35 Gy)
Number of subjects: 27
Study 12163992 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 27
Study 10195522 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPS) pretreatment
Number of subjects: 0
Study 10195522 — intervention group
Group type: COMPARATOR
Intervention: Control (no MPS pretreatment)
Number of subjects: 0
Study 7486115 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol blood concentration 1 microgram/mL
Number of subjects: 14
Study 7486115 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol blood concentration 2 micrograms/mL
Number of subjects: 14
Study 7486115 — intervention group
Group type: COMPARATOR
Intervention: No propofol
Number of subjects: 14
Study 7486115 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol blood concentration
Number of subjects: 14
Study 7486115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index
Number of subjects: 14
Study 7486115 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% spectral edge frequency
Number of subjects: 14
Study 7486115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index vs. propofol concentration
Number of subjects: 14
Study 7486115 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% spectral edge frequency vs. propofol concentration
Number of subjects: 14
Study 2403089 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale
Number of subjects: 15
Study 2403089 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Coma Score
Number of subjects: 15
Study 2403089 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Orthopedic Hospital and Medical Center Scale
Number of subjects: 15
Study 2403089 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 to IV Scale
Number of subjects: 15
Study 2403089 — intervention group
Group type: EXPERIMENTAL
Intervention: Simpson and Reilly Scale
Number of subjects: 15
Study 2403089 — intervention group
Group type: EXPERIMENTAL
Intervention: Jacobi Scale
Number of subjects: 15
Study 6769773 — intervention group
Group type: COMPARATOR
Intervention: Oral thioctic acid for 21 days
Number of subjects: 20
Study 6769773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thioctic acid for 21 days
Number of subjects: 20
Study 6769773 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 20
Study 30999123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignore condition
Number of subjects: 191
Study 30999123 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge condition
Number of subjects: 191
Study 30999123 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassured condition
Number of subjects: 191
Study 30999123 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocated condition
Number of subjects: 191
Study 29068995 — intervention group
Group type: EXPERIMENTAL
Intervention: PASAT distraction during chest compressions
Number of subjects: 44
Study 29068995 — intervention group
Group type: COMPARATOR
Intervention: No PASAT distraction during chest compressions
Number of subjects: 44
Study 25403264 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (POM+LoDEX)
Number of subjects: 455
Study 25403264 — intervention group
Group type: COMPARATOR
Intervention: High-dose dexamethasone (HiDEX)
Number of subjects: 455
Study 24687833 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus mFOLFOX6
Number of subjects: 285
Study 24687833 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus mFOLFOX6
Number of subjects: 285
Study 23095185 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA group (200 mg/day DHA)
Number of subjects: 120
Study 23095185 — intervention group
Group type: COMPARATOR
Intervention: Control group (pooled controls)
Number of subjects: 120
Study 19544822 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser + Clearfil SE Bond
Number of subjects: 30
Study 19544822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate + Clearfil SE Bond
Number of subjects: 30
Study 19544822 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond
Number of subjects: 30
Study 19544822 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond
Number of subjects: 30
Study 17634485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolatrexed (NOL)
Number of subjects: 445